VZL 2008, 77(2):50-52

Electrocardiography in Diagnostics of Cardiac Toxicity of Oncology Treatment

Jan M. Horáček ORCID...1,2, Ladislav Jebavý1,2, Radek Pudil3, Martin Jakl ORCID...4, Ladislav Slováček1, Miroslav Brndiar1, Jaroslav Kačerovský1
1 Univerzita obrany, katedra válečného vnitřního lékařství Fakulty vojenského zdravotnictví, Hradec Králové
2 II. interní klinika - oddělení klinické hematologie, Fakultní nemocnice Hradec Králové a Lékařská fakulta Univerzity Karlovy v Hradci Králové
3 I. interní klinika, Fakultní nemocnice Hradec Králové a Lékařská fakulta Univerzity Karlovy v Hradci Králové
4 Univerzita obrany, Fakulta vojenského zdravotnictví, Hradec Králové

Kardiotoxicita je jedním z možných nežádoucích účinků onkologické léčby. K diagnostice kardiotoxicity byla doporučena řada metod. V našich podmínkách se rutinně používá elektrokardiografie a echokardiografie. Článek podává přehled o možnostech elektrokardiografie v diagnostice kardiotoxicity onkologické léčby a obsahuje vlastní zkušenosti autorů s touto problematikou.

Keywords: Kardiotoxicita; Elektrokardiografie; Onkologická léčba

Cardiac toxicity is one of the possible adverse events of oncology treatment. Various methods have been recommended for diagnostics of cardiac toxicity. In our conditions, electrocardiography and echocardiography are routinely used. The article gives a review of the potential of electrocardiography in diagnostics of cardiac toxicity of oncology treatment and contains the authors' own experience with this problem.

Keywords: Cardiac toxicity; Electrocardiography; Oncology treatment

Received: October 2, 2007; Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horáček, J.M., Jebavý, L., Pudil, R., Jakl, M., Slováček, L., Brndiar, M., & Kačerovský, J. (2008). Electrocardiography in Diagnostics of Cardiac Toxicity of Oncology Treatment. Vojenské Zdravotnické Listy, 77(2), 50-52
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. SHAN, K. - LINCOFF, AM. - YOUNG, JB. Anthracycline-induced cardiotoxicity. Ann. Intern. Med., 1996, vol. 125, p. 47-58. Go to original source... Go to PubMed...
    2. JONES, RL. - SWANTON, C. - EWER, MS. Anthracycline cardiotoxicity. Expert Opin. Drug Saf., 2006, vol. 5, p. 791-809. Go to original source... Go to PubMed...
    3. MEINARDI, MT., et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat. Rev., 1999, vol. 25, p. 237-247. Go to original source... Go to PubMed...
    4. SORENSEN, K., et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer, 2003, vol. 97, p. 1991-1998. Go to original source... Go to PubMed...
    5. ELBL, L., et al. Diagnostické možnosti pozdních následků kardiotoxické chemoterapie antracykliny. Vnitř. Lék., 2002, roč. 48, s. 981-988.
    6. PRAGA, C., et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat. Rep., 1979, vol. 63, p. 827-834.
    7. NOUSIAINEN, T., et al. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J. Intern. Med., 1999, vol. 245, p. 359-364. Go to original source... Go to PubMed...
    8. GANZ, WI., et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology, 1996, vol. 53, p. 461-470. Go to original source... Go to PubMed...
    9. VON HOFF, DD. - ROZENCWEIG, M. - PICCART, M. The cardiotoxicity of anticancer agents. Semin. Oncol., 1982, vol. 9, p. 23-33.
    10. MINOW, RA., et al. QRS voltage change with adriamycin administration. Cancer Treat. Rep., 1978, vol. 62, p. 931-934. Go to PubMed...
    11. LARSEN, RL., et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am. J. Cardiol., 1992, vol. 70, p. 73-77. Go to original source... Go to PubMed...
    12. SCHWARTZ, CL., et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J. Clin. Oncol., 1993, vol. 11, p. 1906-1910. Go to original source... Go to PubMed...
    13. SARUBBI, B., et al. Ventricular repolarization indexes following anthracycline treatment. Heart Vessels, 1997, vol. 12, p. 262-266. Go to original source... Go to PubMed...
    14. JAKL, M. - HORÁČEK, JM. Elektrokardiografické monitorování akutní kardiotoxicity antracyklinů. Voj. zdrav. Listy, 2006, roč. 75, s. 107-110.
    15. O'BRYAN, RM., et al. Phase II evaluation of adriamycin in human neoplasm. Cancer, 1973, vol. 32, p. 1-8. Go to original source...
    16. WORTMAN, JE., et al. Sudden death during doxorubicin administration. Cancer, 1979, vol. 44, p. 1588-1591. Go to original source...
    17. FERRARI, S., et al. The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin. J. Chemother., 1996, vol. 8, p. 232-236. Go to original source... Go to PubMed...
    18. STEINBERG, JS., et al. Acute arrhythmogenicity of doxoruicin administration. Cancer, 1987, vol. 60, p. 1213-1218. Go to original source...
    19. RAABE, NK. - STORSTEIN, L. Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration. An evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring. Acta Oncol., 1991, vol. 30, p. 843-846. Go to original source... Go to PubMed...
    20. ROWINSKY, EK., et al. Cardiac disturbances during the administration of taxol. J. Clin. Oncol., 1991, vol. 9, p. 1704-1712. Go to original source... Go to PubMed...
    21. LOPEZ-DE LA CRUZ, I. - AGUAYO-GONZALEZ, A. - LOPEZ-KARPOVITCH, X. Thalidomide-associated bradycardia in patients with hematologic diseases: a single institution experience. Rev. Invest. Clin., 2006, vol. 58, p. 424-431. Go to PubMed...
    22. SANZ, MA. - TALLMAN, MS. - LO-COCO, F. Tricks of the trade for the appropriate management of acute promyelocytic leukemia. Blood, 2005, vol. 105, p. 3019-3025. Go to original source... Go to PubMed...
    23. GRADISHAR, WJ. - VOKES, EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann. Oncol., 1990, vol. 1, p. 409-414. Go to original source... Go to PubMed...
    24. FRICKHOFEN, N., et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann. Oncol., 2002, vol. 13, p. 797-801. Go to original source... Go to PubMed...
    25. BERLINER, S., et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest., 1990, vol. 8, p. 583-586. Go to original source... Go to PubMed...
    26. YEH, ET., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation, 2004, vol. 109, p. 3122-3131. Go to original source... Go to PubMed...
    27. DAVIS, MJ., et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood, 1990, vol. 75, p. 781-786. Go to original source...
    28. KEUNG, YK., et al. Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transplant., 1994, vol. 14, p. 363-367. Go to PubMed...
    29. BAZETT, HC. An analysis of the time relations of electrocardiograms. Heart, 1920, vol. 7, p. 353-370.
    30. http://www.cancer.gov, NCI Common Terminology Criteria for Adverse Events v3.0

    Return to the content